Skip to main content
    V

    VistaGen Therapeutics Inc (VTGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.18
    +0.00 (+2.11%)

    Market Cap: $8.01M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    VistaGen Therapeutics Inc (VTGN) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect VistaGen Therapeutics (VTGN) to earn -$1.48 per share in the fiscal year ending Mar 31, 2027, on revenue of $1.70M. Of 4 analysts, 0 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Mar 31, 2027 were revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 3.00, inside the Hold band from 2.5 up to 3.5. All 4 rate it Hold.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy00.0%
    Hold4100.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Hold
    Total analysts
    4

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss.

    Fiscal year ending Mar 31, 2027
    -$1.48
    EPS consensus, revenue $1.70M
    Fiscal year ending Mar 31, 2028
    -$1.54
    EPS consensus
    Next report
    Feb 10, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Mar 31, 2027-$1.48-$1.50 to -$1.452$1.70M$1.50M to $1.90M2
    Mar 31, 2028-$1.54-$1.54 to -$1.541N/AN/A1

    Quarterly Estimates

    The EPS consensus is -$0.37 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.37-$0.37 to -$0.362$250000N/A2
    Mar 31, 2027-$0.37N/A4$255000N/A4

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 5 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Mar 31, 202702
    Fiscal year ending Mar 31, 202801
    Quarter ending Dec 31, 202602

    EPS Trend

    The EPS consensus for the fiscal year ending Mar 31, 2027 is where it was 90 days ago.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Mar 31, 2027-$1.48-$1.45-$1.45-$1.48-$1.48N/A
    Fiscal year ending Mar 31, 2028-$1.54-$1.54-$1.54-$1.54-$1.11N/A
    Quarter ending Dec 31, 2026-$0.37-$0.36-$0.36-$0.37-$0.37N/A

    Frequently Asked Questions About VTGN

    What is the VTGN stock forecast?

    Consensus analyst estimates put VistaGen Therapeutics's EPS at -$1.48 for the fiscal year ending Mar 31, 2027, on revenue of $1.70M. The consensus rating from 4 analysts is Hold.

    How do analysts rate VTGN stock?

    Of 4 analysts covering VistaGen Therapeutics, 0 rate it Strong Buy, 0 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from VTGN next year?

    For the fiscal year ending Mar 31, 2027, the consensus EPS estimate is -$1.48, with estimates from -$1.50 to -$1.45 from 2 analysts. For the fiscal year ending Mar 31, 2028, the consensus EPS estimate is -$1.54, with estimates from -$1.54 to -$1.54 from 1 analyst.

    What revenue do analysts expect from VistaGen Therapeutics next year?

    For the fiscal year ending Mar 31, 2027, the consensus revenue estimate is $1.70M, with estimates from $1.50M to $1.90M.

    How many analysts cover VTGN?

    4 analysts rate VistaGen Therapeutics stock, and 2 analysts estimate its EPS for the fiscal year ending Mar 31, 2027.